Anglo-Swedish drugmaker AstraZeneca has inaugurated a new $100 millionmanufacturing plant in China, which it says is "one of the largest investments by a western pharmaceuticals company in the People's Republic." The facility, which is located in Wuxi New District, 200 kilometres north west of Shanghai, covers a total area of 96,000 square meters.
The plant's estimated annual production capacity will be 1.5 billion tablets, 70 million capsules, 2.5 million bottles of oral solutions,four million bottles of dose-aerosols/sprays and some six million vials of sterile products. Among the products to be manufactured at the site are the group's best-selling antiulcerant Losec (omeprazole) and the calcium antagonist Plendil (felodipine). The plant employs 280 people.
AstraZeneca has also unveiled plans to create a center of excellence at its facility in Bangalore, India, specializing in new medicines of importance to the developing world, and will focus principally on finding a new treatment for tuberculosis, a disease which currently affects two million people every year in India. The investment program will include $10 million to create new laboratories in Bangalore, and a further $5 million to support research activities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze